Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Phase 2
Completed
NCT00621296
| Condition | Hepatitis C |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Tanabe Pharma Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 15 participants |
|---|
| Interventions | MP-424 (Telaprevir) |
|---|
| Start date | Jan, 2008 |
|---|
| Completion date | Feb, 2009 |
|---|
| Results posted | Oct 19, 2012 |
|---|
Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
24 Weeks After Completion of Drug Administration (dosing period is 24 Weeks) or drug withdrawal. The subjects were assessed at 24 weeks following the last dose of study drug. · participants
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.